Nuclear magnetic resonance and radionuclide angiographic assessment of acute myocardial infarction in a randomized trial of intravenous streptokinase

Reproducibility of Chronic and Acute Infarct Size Measurement by Delayed Enhancement-Magnetic Resonance Imaging

OBJECTIVES

The aim of this study was to evaluate the reproducibility of acute and chronic infarct size (IS) by delayed enhancement (DE) magnetic resonance imaging (MRI).

BACKGROUND

Infarct size measurements can be used as surrogate end point to reduce the sample size in studies comparing different reperfusion strategies in myocardial infarction (MI). Delayed enhancement MRI is a rather new technique, and so far infarct IS reproducibility has not been established appropriately.

METHODS

In 21 patients (10 acute MI and 11 chronic MI), IS was assessed repeatedly on consecutive days by DE-MRI. Reproducibility, interobserver, and intraobserver variabilities were assessed and compared by the Bland-Altman method.

RESULTS

Acute and chronic IS were 17.1 +/- 19.6% (range 5.1% to 69.8%) of LV mass (%LV) and 16.9 +/- 9.9 %LV (range 2.0% to 36.0%), respectively. Infarct size difference (bias) between scan I and scan II was -0.5 %LV, and limits of agreement were +/-2.4 %LV. Mean bias (-0.7 %LV) and limits of agreement (+/-3.2%) were slightly higher for acute in comparison with chronic MI with -0.4 +/- 1.3 %LV. Intraobserver and interobserver variability was low with a mean bias of 0.3 %LV (limits of agreement +/- 1.7 %LV) and -0.7 %LV (limits of agreement +/- 2.2 %LV), respectively.

CONCLUSIONS

Infarct size measurement by DE-MRI is an excellent tool for IS assessment, owing to its excellent repeatability in chronic and acute MI. It has therefore the potential to serve as a surrogate end point to uncover advantages of new reperfusion strategies.

The quantification of infarct size

We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

We propose the adaptation of classical monitoring boundaries for use in cumulative meta-analysis as guidelines for deciding when accumulating evidence is statistically significant and medically convincing. The interpretation of information from a randomized controlled trial is compared with that from a meta-analysis. The concept of optimal information size for a meta-analysis is developed and used to adapt monitoring boundaries to cumulative meta-analysis.

The determination of myocardial viability using Gd-DTPA in a canine model of acute myocardial ischemia and reperfusion

The partition coefficient of Gd-DTPA was thought to vary with the amount of cellular membrane damage after an acute myocardial infarction. The relationship between the partition coefficient of Gd-DTPA (lambda) and the uptake of 201Tl (as a marker of tissue viability) was studied 2 h to 3 weeks after reperfusion of a 2-h occlusion to the left anterior descending coronary artery in a canine model. Gd-DTPA was infused as a bolus followed by a prolonged constant infusion, and this infusion protocol was optimized such that the concentration of Gd-DTPA was directly related to lambda. After this infusion, MR images of excised hearts showed regions of increased signal intensity corresponding to increased Gd-DTPA concentration. At all time points, lambda and 201Tl uptake were strongly negatively correlated indicating that lambda is an accurate indicator of myocardial viability. Furthermore, lambda in the infarcted regions was increased relative to normal regions after 2 h of reperfusion and stayed elevated up to 3 weeks. At all time points, lambda in the infarcted and normal regions were significantly different. As well, this data showed a trend that lambda in infarcted regions decreased monotonically from 1 day to 3 weeks. This trend was confirmed with MR imaging by examining the change in signal intensity of in vivo images from 4 days to 3 weeks in two animals. These results suggest that MRI with Gd-DTPA could be used to measure the extent of myocardial damage after an acute myocardial infarction.

Magnetic resonance techniques for assessment of myocardial viability

In general, the following three standards for myocardial viability can be used: (a) preserved coronary flow (adequate perfusion); (b) preserved wall motion (systolic wall thickening); and (c) preserved metabolism (metabolic integrity). The current magnetic resonance (MR) techniques provide a great potential to measure all three standards of viability. Adequate perfusion can be assessed by spin-echo MR imaging and/or ultrafast MR imaging, systolic wall thickening by cine MR imaging, and the presence of metabolic integrity can be determined by MR spectroscopy. These noninvasive and versatile techniques have led to an increasing interest and research in recent years. Particular strengths of the MR techniques are: the inherent three-dimensional data acquisition without radiation exposure; the intrinsic soft-tissue contrast that allows tissue characterization; the excellent spatial resolution (in the 1- to 2-mm range), which permits the evaluation of regional abnormalities; multitomographic imaging capabilities that allow acquisition of cardiac images in any plane; the inherent sensitivity to blood and wall motion; and the potential for in vivo measurement of myocardial metabolism using MR spectroscopy. This review article demonstrates that MR techniques might play a growing role in the assessment of myocardial viability.

Magnetic resonance imaging in coronary artery disease

The cardiovascular applications of nuclear magnetic resonance (MR) techniques in coronary artery disease have increased considerably in recent years. Technical advantages of MR imaging in comparison with other techniques are the excellent spatial resolution, the characterization of myocardial tissue, and the potential for three-dimensional imaging. This allows the accurate assessment of left ventricular mass and volume, the differentiation of infarcted tissue from normal myocardial tissue, and the determination of systolic wall thickening and regional wall motion abnormalities. Myocardial perfusion, metabolism, and inducible myocardial ischemia with the use of pharmacological stress also can be assessed by MR techniques. Future technical improvements in real-time imaging and development of noninvasive visualization of the coronary arteries and coronary artery bypasses will constitute a tremendous progress in clinical cardiology. Early detection and flow assessment of stenosed coronary arteries by MR angiography with the use of flow velocity measurements may outweigh the cost inherent to the MR imaging procedure. A particular strength of the MR technique is the potential to encompass cardiac anatomy, perfusion, function, metabolism, and coronary angiography in a single test. The replacement of multiple diagnostic tests with one MR test may have major effects on cardiovascular healthcare economics.

Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy

The purpose of this study was to determine the extent to which patients with cardiogenic shock have participated in trials of thrombolytic therapy, to examine factors associated with their exclusion from these trials, and to summarize data on the efficacy of thrombolysis in these patients. Previous publications were searched for all randomized, controlled studies involving the use of thrombolytic medications used in the treatment of acute myocardial infarction. Data were abstracted for year of trial publication, performance location, sample size, maximal allowable delay between symptom onset and treatment, and exclusion criteria. Of the 94 trials included in the analysis, 22% included patients with cardiogenic shock, 37% excluded them, and the remainder contained no information on their inclusion or exclusion. Only 2 trials provided data on the efficacy of thrombolytic therapy in patients with cardiogenic shock. Multivariate analysis revealed that studies conducted exclusively in the U.S. were significantly more likely to exclude patients in cardiogenic shock than those conducted outside of the U.S., as were studies that excluded patients with a previous myocardial infarction, studies published more recently, and smaller trials. Patients with cardiogenic shock have frequently been excluded from clinical trials of thrombolytic agents. As a result, data on the efficacy of thrombolytic agents in these patients is extremely limited.

Human brain measures of clinical pain: a review. II. Tomographic imagings

This paper (Parts I and II) reviews the measures employed in studying the brain neurophysiological activities of clinical pain. In Part II, these measures include the imaging and measurement of brain blood flow and hemodynamics in various regions of the brain, the scanning of gross and fine brain structures by computerized axial tomography or magnetic resonance imaging, and the imaging and measurement of brain metabolic changes, energy uptake, and receptors bindings through positron emission tomography or single-photon emission computerized tomography. Molecular chemical transformation by the nuclear magnetic resonance analysis of tissue changes and analgesic-receptor interactions is also noted. Most studies of the cerebral measures of traumatic and pathophysiological pain reported in the literature are concerned with headache. The relationships of brain activities among sensory processes of nociception, subjective experience of pain intensity and quality, emotional reaction, and cognitive coping often are complex and not well elucidated in man. Although significant changes in the cerebral physiological parameters are frequently reported in pain patients, the specificity and sensitivity of these measures as objective markers for human pain, reviewed from Part I and Part II together, has not yet been conclusively defined. Also, normative data basis and criteria for classifying abnormality of these brain measures must be established and their validity and reliability be carefully examined so that they can be confidently applied in diagnosis and management of clinical pain. Nevertheless, advancement on measurement of temporal dynamics in 3-D topographic mapping of cortical activities and source localization modeling, together with tomographic imaging of neurochemical metabolisms in the brain will further our scientific understanding of cerebral pain mechanisms. A window on the brain of human pain is being opened.

Comparison of magnetic resonance imaging studies with enzymatic indexes of myocardial necrosis for quantification of myocardial infarct size

To evaluate the potential of gadolinium-diethylene triamine pentaacetic acid (DTPA)-enhanced magnetic resonance imaging (MRI) in the quantification of infarct size in patients with a first acute myocardial infarction, 24 patients with a first acute myocardial infarction were studied by electrocardiographic gated MRI at a mean of 4.3 days after the acute event. Multislice, single-phase, T1-weighted, spin-echo MRI in the true short-axis plane was performed 20 minutes after intravenous injection of gadolinium-DTPA (0.15 mmol/kg of body weight). Circumscript myocardial regions of increased signal intensity on gadolinium-DTPA-enhanced images were considered to be infarcted. Infarct size (in g) was determined using Simpson's rule, and was compared with that based on cumulative release of alpha-hydroxybutyrate dehydrogenase activity in plasma and with peak creatine kinase-MB level in plasma. Infarct size quantified with MRI correlated well with "enzymatic" infarct size (in g equivalents) (y = 0.99 x + 0.71; r = 0.93; p = 0.0001) and peak creatine kinase-MB levels (r = 0.72; p = 0.002). It is concluded that gadolinium-DTPA-enhanced MRI enables accurate quantification of infarct size in patients with a first acute myocardial infarction.

Phosphonate-modified Gd-DTPA complexes. III: The detection of myocardial infarction by MRI

The potential of a phosphonate-modified-Gd-DTPA for MR image enhancement of myocardial infarction has been demonstrated in imaging experiments on rats. The agent, 1-hydroxy-3-aminopropane-1,1-diphosphonate-modified-Gd-DTPA (Gd-DTPA-HPDP) accumulates in two models of myocardial infarction, (i.e., drug-induced diffusely infarcted whole hearts and in focal acute myocardial infarction from a left coronary artery ligation). The time course of the accumulation of the agent in the focal model of infarction and subsequent washout has also been followed in vitro. Results of this kinetics demonstrate that the agent first perfuses all normal fluid spaces and then slowly diffuses into the occluded zone where it is retained for a prolonged period, in sufficient quantities to be useful as an MRI contrast agent. Wash-out of the agent from normal myocardium is fast and complete with MR signal returning to background in minutes. The specificity of Gd-DTPA-HPDP for soft-tissue calcification and its retention within the infarcts permitted imaging at 1 to 2 h postinjection, (after unbound material has cleared the normal tissues). Infarcted tissue appeared as regions of increased signal intensity in T1-weighted images (> 200% enhancement), and correlated with histopathology. Unmodified Gd-DTPA was not retained under identical conditions. Gd-DTPA-HPDP permits a more accurate infarct delineation than is possible with the unmodified agent.

Assessment of residual viability in patients with myocardial infarction using magnetic resonance techniques

Magnetic resonance techniques have only recently been employed to assess residual myocardial viability after myocardial infarction. Three approaches have been described to achieve this purpose: First, the use of signal intensity changes on spin-echo images with and without the application of contrast media to define irreversible injury to the myocardium in acute and subacute infarcts; second, measurement of metabolite concentrations within the infarct area using magnetic resonance spectroscopy, and third, quantitation of myocardial thickness and systolic wall thickening in chronic infarcts. This paper reviews the pertinent literature and compares MR techniques with other imaging techniques used in the diagnosis of myocardial viability.

Left ventricular wall motion analysis in patients with acute myocardial infarction using magnetic resonance imaging

Dynamic magnetic resonance (MR) imaging of the left ventricle was performed in 13 patients with acute myocardial infarction and in 11 healthy volunteers. Visual assessment of cine MR video loops correctly located the infarction of 12 of 13 patients. Quantitative analysis of absolute and relative wall thickening, area ejection fraction, and radial shortening fraction accurately distinguished hearts with and without infarction (p < .001). This distinction could also be made using the number of segments with decreased and the number of segments with decreased + increased wall motion (p < .001). Localization of the infarction by quantitative MR methods was limited, probably due to relative low temporal resolution. Combined evaluation of qualitative and quantitative MR imaging data provides useful information on wall motion dynamics after acute myocardial infarction.

Intravenous streptokinase in acute myocardial infarction (I.S.A.M.) trial: serial evaluation of left ventricular function up to 3 years after infarction estimated by radionuclide ventriculography. I.S.A.M. Study Group

The Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.) trial was a prospective, placebo-controlled, double-blind multicenter trial of high-dose short-term intravenous streptokinase in acute myocardial infarction administered within 6 h after the onset of symptoms. Global and regional left ventricular ejection fractions were determined by radionuclide ventriculography in a subset of 120 patients 3 days, 4 weeks, 7 months, 18 months and 3 years after acute myocardial infarction. In patients with anterior myocardial infarction, left ventricular ejection fraction was higher in the streptokinase than in the placebo group 3 days after acute infarction (49 +/- 14% vs. 40 +/- 11%, p = 0.02). This difference of about 10% units in ejection fraction persisted during the 3 year follow-up period. Among streptokinase-treated patients, regional left ventricular ejection fraction was higher within the infarct zone as well as in remote myocardium throughout the follow-up period. Among patients with inferior infarction, no significant differences between the treatment and control groups were demonstrable with respect to global and regional left ventricular ejection fraction. Thus, intravenous administration of streptokinase within 6 h after the onset of symptoms of acute myocardial infarction preserves left ventricular function over a period of greater than or equal to 3 years in patients with acute anterior myocardial infarction. It improves regional myocardial function within the infarct zone as well as in remote areas. In patients with acute inferior myocardial infarction, benefit from intravenous streptokinase is of only minor degree.

Magnetic resonance imaging of myocardial infarction: correlation with enzymatic, angiographic, and radionuclide findings

Spin-echo cardiac magnetic resonance imaging studies were performed in 20 patients with a first 7- to 14-day-old (mean 10) myocardial infarction. The magnetic resonance imaging findings were compared with coronary angiography (14 patients), myocardial enzyme release (18 patients), radionuclide angiography (19 patients), and thallium-201 perfusion scintigraphy (19 patients). Regional T2 relaxation times determined from the signal intensities at echo times 30 msec and 90 msec were significantly prolonged in the infarcted areas. Based on abnormal T2 times for every patient, a regional and a total myocardial damage score was determined. The infarct-related artery was correctly identified in 93% of patients by magnetic resonance imaging, in 79% of patients by thallium-201 scintigraphy, and in 62% of patients by radionuclide angiography. The total damage score correlated well with enzymatic infarct size (r = 0.75, p less than 0.001). The correlation between left ventricular end-systolic volume index determined by magnetic resonance imaging and by radionuclide angiography was r = 0.89 (p less than 0.002). The left ventricular end-systolic volume index correlated significantly with enzymatic infarct size (r = 0.72, p less than 0.001), total damage score (r = 0.68, p less than 0.002), and radionuclide left ventricular ejection fraction (r = -0.68, p less than 0.002). Correlations between the magnetic resonance damage score and the thallium-201 perfusion score were r = 0.60 (p less than 0.01) for the exercise images, and r = 0.72 (p less than 0.001) for the redistribution images. This study shows that spin-echo magnetic resonance imaging is quite comparable with the established noninvasive imaging modalities currently used in patients with acute myocardial infarction.

Myocardial infarct sizing and assessment of reperfusion by magnetic resonance imaging: a review

Early thrombolytic therapy restores patency of thrombotic coronary artery occlusion in many patients. Intravenous streptokinase appears to be effective in achieving recanalization of the occluded infarct-related artery, thereby reducing myocardial infarct size. However, it may be difficult to assess non-invasively the relative value of different reperfusion therapies. MR imaging with or without the use of contrast agents may become a reliable non-invasive technique to assess infarct size after reperfusion therapy. There are indications that early MR imaging after administration of Gd-DTPA is able to differentiate reperfused from non-reperfused infarcts. Furthermore, MR infarct sizing using Gd-DTPA can demonstrate infarct size reduction in patients with successful reperfusion. The availability of ultrafast imaging methods and MR contrast agents may allow assessment of myocardial perfusion in the near future. This article reviews the current status of MR imaging for evaluating ischemic myocardial disease.

Detection and quantification of recent myocardial infarction: diagnostic value of multiecho multislice spin echo imaging

Thirty-four patients with documented transmural MI were studied with gated three echo, multislice MR imaging. In 12 patients MRI MI size was compared with CK release measurement, Tl-201 SPECT defect, and with Tc-99m LVEF. Infarct was visualised in 29/34 patients on 3rd echo images (18/34 on 2nd and 6/34 on 1st echo images). Mean MR infarct size (planimetered from 3rd echo images): 33.1 +/- 9% overestimated the SPECT defect (mean value of 23.8 +/- 15%). However, the overall correlation between MRI and Tl-201 sizing was significant: r = 0.82; p less than 0.001; SEE = 5.5%. The correlation with LVEF also appeared significant: r = -0.61; p less than 0.038.

Acute myocardial infarction: comparison of T2-weighted and T1-weighted gadolinium-DTPA enhanced MR imaging

Magnetic resonance images were obtained from 32 patients with acute myocardial infarction, using a four-echo technique (echo time (TE) = 30, 60, 90, and 120 ms) pregadolinium(Gd)-DTPA injection and a TE = 30 ms sequence pre- and post-Gd-DTPA. Intensity ratios of infarcted and normal myocardium were calculated, as were contrast-to-noise and signal-to-noise ratios. The four intensity ratios pre-Gd-DTPA were 1.20 +/- 0.15, 1.42 +/- 0.22, 1.78 +/- 0.38, and 1.99 +/- 0.60 for TE = 30, 60, 90, and 120 ms, respectively, and 1.42 +/- 0.19 post-Gd-DTPA (p = NS for post-Gd-DTPA vs TE = 60, p = 0.007 for TE = 90 vs TE = 120, p less than 0.0001 for all other comparisons). The four contrast-to-noise ratios pre-Gd-DTPA were 1.69 +/- 0.97, 2.69 +/- 1.13, 3.17 +/- 1.15, and 2.90 +/- 1.09 for TE = 30, 60, 90, and 120 ms, respectively, and 2.71 +/- 1.26 post-Gd-DTPA (p = NS for post-Gd-DTPA vs TE = 60, 90, and 120, p = NS for TE = 120 vs TE = 60 and 90, p less than 0.01 for all other comparisons). The four signal-to-noise ratios pre-Gd-DTPA were 8.67 +/- 1.47, 6.52 +/- 0.76, 5.20 +/- 0.64, 4.17 +/- 0.53 for TE = 30, 60, 90, and 120 ms, respectively, and 9.17 +/- 1.92 post-Gd-DTPA (p = 0.03 for post-Gd-DTPA vs TE = 30, p less than 0.0001 for all other comparisons). In conclusion, the detectabilities of acute myocardial infarction were similar at TE = 60 ms and at Gd-DTPA enhanced short-TE MR imaging. However, image quality proved to be superior using the Gd-DTPA enhanced short-TE technique.

Clinical cardiovascular magnetic resonance imaging

Magnetic resonance imaging (MRI) is a powerful tool providing high-resolution images of the heart and great vessels without the use of ionizing radiation or contrast agents. MRI systems currently in use at many hospitals can be used effectively in the routine, clinical evaluation of many forms of cardiovascular disease, including great vessel disease, ischemic cardiac disease and congenital cardiac disease. Moreover, quantitative and cine MRI techniques are now available, which provide highly accurate measures of chamber size, wall motion and wall thickening. Recent developments in the areas of myocardial tagging, high-speed imaging and MR assessments of flow and perfusion suggest potential for an increasing role of MRI in the clinical evaluation of the cardiovascular system.

Infarct sizing by scintigraphic techniques and nuclear magnetic resonance imaging

Assessment of myocardial infarct size is the cornerstone in the evaluation of interventions designed to salvage myocardium, such as thrombolytic therapy and urgent coronary angioplasty. Enzymatic methods have probably the highest accuracy but can only be used in the very early phase of infarction. The electrocardiogram allows a reasonable estimate of infarct size, but its confidence limits are wide, and in inferior wall infarction the estimates are unreliable. In recent years, radionuclide techniques have been successfully used to identify, localize and determine infarct size in the course of acute myocardial infarction. These scintigraphic measurements have provided important diagnostic, therapeutic and prognostic information based on the extent of myocardial damage. Nuclear magnetic resonance imaging, particularly with contrast enhancement, is one of the methods that have the greatest potential in accurately delineating myocardial infarct size. Nuclear medicine procedures, on the other hand, employ more biologically oriented tracers and offer promise in view of their ability to monitor biochemical alterations as an effect of therapy in the course of myocardial infarction.

Diagnostic significance of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in thrombolytic treatment for acute myocardial infarction: its potential in assessing reperfusion

The diagnostic value of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in patients treated by thrombolysis for acute myocardial infarction was assessed in 27 consecutive patients who had a first acute myocardial infarction (14 anterior, 13 inferior) and who underwent thrombolytic treatment and coronary arteriography within 4 hours of the onset of symptoms. Magnetic resonance imaging was performed 93 hours (range 15-241) after the onset of symptoms. A Philips Gyroscan (0.5 T) was used, and spin echo measurements (echo time 30 ms) were made before and 20 minutes after intravenous injection of 0.1 mmol/kg gadolinium-DTPA. In all patients contrast enhancement of the infarcted areas was seen after Gd-DTPA. The signal intensities of the infarcted and normal values were used to calculate the intensity ratios. Mean (SD) intensity ratios after Gd-DTPA were significantly increased (1.15 (0.17) v 1.52 (0.29). Intensity ratios were higher in the 17 patients who underwent magnetic resonance imaging more than 72 hours after the onset of symptoms than in the 10 who underwent magnetic resonance imaging earlier, the difference being significantly greater after administration of Gd-DTPA (1.38 (0.12) v 1.61 (0.34). When patients were classified according to the site and size of the infarcted areas, or to reperfusion (n = 19) versus non-reperfusion (n = 8), the intensity ratios both before and after Gd-DTPA did not show significant differences. Magnetic resonance imaging with Gd-DTPA improved the identification of acutely infarcted areas, but with current techniques did not identify patients in whom thrombolytic treatment was successful.